Andrew Brackmann's questions to Neogenomics Inc (NEO) leadership • Q1 2025
Question
Andrew Brackmann of William Blair & Company asked CEO Tony Zook about his initial 30 days at the helm, sources of optimism, and areas requiring more attention. He also inquired about the drivers behind the 22% of clinical revenue from five new NGS products and the expected growth trajectory for the upcoming PanTracer liquid biopsy test.
Answer
CEO Anthony Zook stated his initial observations confirmed his positive outlook, highlighting the talented management team and strong Q1 performance, while acknowledging headwinds in the pharma business. President & COO Warren Stone explained that while a couple of the five new NGS products have a larger contribution, all are meaningful. He noted the success is due to a combination of relevant products and strategic sales force expansion, which aligns with the upcoming PanTracer launch, fueling optimism for continued penetration in community oncology.